When administered together, their mechanisms converge to amplify appetite regulation, energy intake reduction, and glycemic improvements, exceeding the individual effects of monotherapy by acting on complementary neuroendocrine circuits regulating body weight and metabolism 1-3
When used with insulin or sulfonylureas, tirzepatide increases the risk of hypoglycemia, requiring careful monitoring
[DOI] [PubMed] [Google Scholar] 20.Kim S.H., Kiick K.L
(Primary source for heart rate data) Ilkiw JL, Charman SA, Gao X, et al
Recent clinical trials, including a new head-to-head study, have further corroborated these findings, confirming that Tirzepatide leads to more significant reductions in body mass on average than Semaglutide